Grace Therapeutics, Inc (GRCE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 25.21 is considered Undervalued compared with the five-year average of -3.08. The fair price of Grace Therapeutics, Inc (GRCE) is between 49.04 to 54.21 according to relative valuation method. Compared to the current price of 4.15 USD , Grace Therapeutics, Inc By Undervalued By 91.54%.

Relative Value

Fair Zone

49.04-54.21

Current Price：4.15

91.54%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Grace Therapeutics, Inc (GRCE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Grace Therapeutics, Inc (GRCE) has a current Price-to-Book (P/B) ratio of 0.82. Compared to its 3-year average P/B ratio of 0.63, the current P/B ratio is approximately 30.74% higher. Relative to its 5-year average P/B ratio of 0.63, the current P/B ratio is about 30.74% higher. Grace Therapeutics, Inc (GRCE) has a Forward Free Cash Flow (FCF) yield of approximately -21.21%. Compared to its 3-year average FCF yield of -33.55%, the current FCF yield is approximately -36.77% lower. Relative to its 5-year average FCF yield of -33.55%, the current FCF yield is about -36.77% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GRCE competitors is 1293.54, providing a benchmark for relative valuation. Grace Therapeutics, Inc Corp (GRCE.O) exhibits a P/S ratio of 25.21, which is -98.05% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GRCE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GRCE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GRCE currently overvalued or undervalued?

Grace Therapeutics, Inc (GRCE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 25.21 is considered Undervalued compared with the five-year average of -3.08. The fair price of Grace Therapeutics, Inc (GRCE) is between 49.04 to 54.21 according to relative valuation method. Compared to the current price of 4.15 USD, Grace Therapeutics, Inc is Undervalued By 91.54%.

What is Grace Therapeutics, Inc (GRCE) fair value?

GRCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Grace Therapeutics, Inc (GRCE) is between 49.04 to 54.21 according to relative valuation method.

How does GRCE's valuation metrics compare to the industry average?

The average P/S ratio for GRCE's competitors is 1293.54, providing a benchmark for relative valuation. Grace Therapeutics, Inc Corp (GRCE) exhibits a P/S ratio of 25.21, which is -98.05% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Grace Therapeutics, Inc (GRCE) as of Mar 02 2026?

As of Mar 02 2026, Grace Therapeutics, Inc (GRCE) has a P/B ratio of 0.82. This indicates that the market values GRCE at 0.82 times its book value.

What is the current FCF Yield for Grace Therapeutics, Inc (GRCE) as of Mar 02 2026?

As of Mar 02 2026, Grace Therapeutics, Inc (GRCE) has a FCF Yield of -21.21%. This means that for every dollar of Grace Therapeutics, Inc's market capitalization, the company generates -21.21 cents in free cash flow.

What is the current Forward P/E ratio for Grace Therapeutics, Inc (GRCE) as of Mar 02 2026?

As of Mar 02 2026, Grace Therapeutics, Inc (GRCE) has a Forward P/E ratio of -3.23. This means the market is willing to pay $-3.23 for every dollar of Grace Therapeutics, Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Grace Therapeutics, Inc (GRCE) as of Mar 02 2026?

As of Mar 02 2026, Grace Therapeutics, Inc (GRCE) has a Forward P/S ratio of 25.21. This means the market is valuing GRCE at $25.21 for every dollar of expected revenue over the next 12 months.

GRCE Valuation